Bank of Montreal’s Elicio Therapeutics ELTX Stock Holding History

Bank of Montreal’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21	Closed	-$3K	–	4027
2021 Q1	$3K	Buy	+21	New	+$4.05K	﹤0.01%	4812

Other funds holding ELTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of Montreal's ELTX Position: Q2 2021 in Review

Bank of Montreal sold out of Elicio Therapeutics (ELTX) in Q2 2021, closing a stake of 21 shares — an estimated $3K sold.

Bank of Montreal first reported a position in ELTX in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 41 funds tracked by Wall St. Rank hold ELTX as of Q2 2021.

Bank of Montreal reported no remaining Elicio Therapeutics position as of Q2 2021 after selling out during the quarter.
Bank of Montreal sold 21 Elicio Therapeutics shares in Q2 2021, an estimated $3K.
Bank of Montreal first reported a position in Elicio Therapeutics in Q1 2021 and held it in 1 quarter.
Bank of Montreal's Elicio Therapeutics position peaked at $3K in Q1 2021.
41 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.